Akebia Therapeutics (AKBA) Misses Q3 EPS by 2c

Akebia Therapeutics (NASDAQ: AKBA) reported Q3 EPS of ($0.47), $0.02 worse than the analyst estimate of ($0.45).

For earnings history and earnings-related data on Akebia Therapeutics (AKBA) click here.

You May Also Be Interested In

• LeonaBio (LONA) Price Target Cut to $17 by Citizens Amid Pipeline Development
• Bimergen Energy Corporation (BESS) Reports Q2 EPS of $0.22
• Phillip Securities Reiterates Buy Rating on Sea Ltd. (SE)